Rosewind is a specialty healthcare company focused on developing treatments for urological and related conditions. Rosewind is currently completing phase 3 clinical development for its lead therapeutic candidate Zertane, an orally-disintegrating tablet (ODT) formulated specifically for the on-demand treatment of premature ejaculation (PE). The company’s therapeutic pipeline is supported in part by its first-in-class RedoxSYS System, which provides the only complete assessment of patients’ redox status and enables identification of a broad variety of disorders where redox is implicated.